Grünenthal GmbH and Kyowa Kirin Co., Ltd. have today announced the successful completion of a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio, which comprises 13 brands across six therapeutic areas primarily focused on pain management, includes Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis.
Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Grünenthal intends to fully acquire the remaining 49 percent share via exercising an option at the beginning of 2026. This new enterprise will be branded as Grünenthal Meds.
Gabriel Baertschi, Chief Executive Officer of Grünenthal GmbH, said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Jeremy Morgan, President of Kyowa Kirin International, commented: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality.”
Today, Grünenthal GmbH and Kyowa Kirin Co., Ltd. have announced the successful completion of a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio, which comprises 13 brands across six therapeutic areas primarily focused on pain management, will now be part of a new enterprise called Grünenthal Meds.
Gabriel Baertschi, Chief Executive Officer of Grünenthal GmbH, said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Jeremy Morgan, President of Kyowa Kirin International, commented: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio.”
Grünenthal GmbH and Kyowa Kirin Co., Ltd. have concluded a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio, comprising 13 brands across six therapeutic areas primarily focused on pain management. The new enterprise, to be branded as Grünenthal Meds, will provide life-changing value for hundreds of thousands of patients.
Gabriel Baertschi, Chief Executive Officer of Grünenthal GmbH, said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Jeremy Morgan, President of Kyowa Kirin International, commented: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio.” Grünenthal intends to fully acquire the remaining 49 percent share at the beginning of 2026.
On 2 August 2023, Grünenthal GmbH and Kyowa Kirin Co., Ltd. completed a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio comprises 13 brands across six therapeutic areas, primarily focusing on pain management. The new enterprise, Grünenthal Meds, will be available in seven major European markets through affiliates and in various additional territories worldwide through a network of partners.
Gabriel Baertschi, Chief Executive Officer of Grünenthal GmbH, said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Grünenthal owns a 51 percent majority share in the Joint Venture Collaboration, while Kyowa Kirin owns a 49 percent share. Jeremy Morgan, President of Kyowa Kirin International, commented: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from
The post Grünenthal and Kyowa Kirin International Complete Partnership Agreement to Establish Joint Venture first appeared on BusinessMole.
